ONdrugDelivery’s September 2026 issue on wearable injectors spotlighted research Bold Insight conducted with Synolus Medical. The article, Limits shattered: Ending the autoinjector and wearable injector divide, written by Dr Scott Russo, Founder and CEO of Synolus Medical, makes the case for MiniGo, a new crossover delivery platform designed to eliminate the traditional trade-offs between autoinjectors and wearable injectors.

To understand how patients would respond to the new device, Bold Insight conducted a formal preference study involving 400 current autoinjector users. The data showed that 83% of participants said they would be likely to switch from their current injection therapy to MiniGo, while 94% rated MiniGo as more convenient due to its hands-free administration. The findings reinforced the platform’s core design philosophy, that simplicity, rather than device category, can play a central role in patient confidence and acceptance.

“Our work with MiniGo is a great example of how direct patient feedback can validate a new approach to device design,” said Korey Johnson, Managing Partner at Bold Insight. “When 8 in 10 users say they’d switch from their current therapy they are more familiar with, it signals a meaningful opportunity to rethink the patient experience.”

This study reflects the medical device research Bold Insight regularly conducts for medtech and pharma clients, translating patient behavior into insights that inform product design and development. Read the full article by visiting the ONdrugDelivery website.

About ONdrugDelivery
ONdrugDelivery provides its readers throughout global pharma and biopharma with the latest, most pertinent, high-quality industry information, intelligence, and insights about the ideas, technologies, services, and products the drug delivery sector is developing.

About Bold Insight
Bold Insight is a UX and human factors research agency based in Chicago and London. Executing projects that span the product development life cycle, we conduct user research that informs early product design through global human factors validation. We work with digital, next-generation technology, from medical devices to mobile apps, IFUs to customer journeys. Learn more about our work in healthcare.